SEC Form 4 · accession 0001209191-15-086507

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Dec 21, 2015

Accepted (ET)

Dec 22, 2015 · 10:11 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Dec 21, 2015	M	10,400	$35.64	A	275,684	D
Common Stock^F2,F3	Dec 21, 2015	S	2,300	$117.93	D	273,384	D
Common Stock^F2,F4	Dec 21, 2015	S	3,400	$118.94	D	269,984	D
Common Stock^F2,F5	Dec 21, 2015	S	4,100	$120.07	D	265,884	D
Common Stock^F2,F6	Dec 21, 2015	S	600	$120.65	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	122,700	I	Common Stock held in trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F7	$35.64	Dec 21, 2015	M	10,400	D	—	Feb 1, 2016	Common Stock	10,400	52,800	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $117.93 (range $117.42 to $118.37).
F4Open market sales reported on this line occurred at a weighted average price of $118.94 (range $118.44 to $119.34).
F5Open market sales reported on this line occurred at a weighted average price of $120.07 (range $119.50 to $120.46).
F6Open market sales reported on this line occurred at a weighted average price of $120.65 (range $120.56 to $120.67).
F7Fully vested.